Conference
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
Authors
Gettinger SN; Shepherd FA; Antonia SJ; Brahmer JR; Chow LQM; Juergens RA; Borghaei H; Shen Y; Harbison C; Alaparthy S
Volume
32
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Publication Date
May 20, 2014
Name of conference
50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference place
IL, Chicago
Conference start date
May 30, 2014
Conference end date
June 3, 2014
Conference proceedings
JOURNAL OF CLINICAL ONCOLOGY
Issue
15
ISSN
0732-183X